Method for forming graft layer, method for producing composite, and treatment liquid for forming graft layer
The method improves graft polymerization efficiency by using a treatment liquid with compound B and polymer C, achieving thicker and more dense graft layers with reduced compound usage and environmental impact, addressing inefficiencies in existing techniques.
Patent Information
- Application Number
- JP2022547573
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-09-10
- Filing Date
- 2021-09-06
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2041-09-06
AI Technical Summary
Existing methods for forming polymer films by graft polymerization on base materials are inefficient, leading to high compound usage, environmental impact, and suboptimal graft layer thickness and density.
A method involving a treatment liquid with compound B, polymer C, and solvent D enhances graft polymerization efficiency through excluded volume and gel effects, allowing for a lower compound concentration to achieve longer graft chains and thicker layers with improved biocompatibility and lubricity.
Reduces compound and initiator usage, minimizes environmental burden, and enhances graft layer thickness and density, improving wettability and wear resistance while maintaining biocompatibility.
Smart Images

Figure 0007583821000002 
Figure 0007583821000003 
Figure 0007583821000004
Abstract
Description
[Technical field]
[0001] The present disclosure relates to a method for forming a graft layer, a method for producing a composite, and a treatment liquid for forming a graft layer. [Background technology]
[0002] A technique for forming a polymer membrane by graft polymerization of a compound onto the surface of a substrate is known. Also, a method for forming a polymer membrane using a treatment aqueous solution containing a water-soluble inorganic salt is known. Summary of the Invention
[0003] A method for forming a graft layer according to one embodiment of the present disclosure includes a contacting step of contacting a substrate containing a polymer A with a treatment liquid containing a compound B and a polymer C in a solvent D. The contacting step includes a polymerization step of graft polymerizing the compound B onto the polymer A constituting at least a part of the surface of the substrate.
[0004] Moreover, a treatment liquid according to one embodiment of the present disclosure is a treatment liquid that contains a compound B and a polymer C in a solvent D, and is for forming a graft layer in which the compound B is graft polymerized on at least a part of the surface of a substrate containing a polymer A. [Brief description of the drawings]
[0005] [Figure 1] FIG. 1 is a schematic diagram illustrating the excluded volume effect. [Diagram 2] FIG. 1 is a schematic diagram illustrating a gel effect. [Diagram 3] FIG. 1 is a schematic diagram of an artificial hip joint 1 according to an embodiment of the present disclosure. [Figure 4] FIG. 1 is a schematic diagram of an acetabular cup according to one embodiment of the present disclosure. [Diagram 5] 1 is a graph showing the relationship between the concentration of 2-methacryloyloxyethyl phosphorylcholine in the treatment liquid and the static contact angle of water in Example 1 and Comparative Example 1. [Figure 6]1 is a graph showing the relationship between the concentration of 2-methacryloyloxyethyl phosphorylcholine in a treatment liquid and the thickness of a graft layer in Example 1 and Comparative Example 1. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0006] Hereinafter, one embodiment of the present disclosure will be described in detail. Unless otherwise specified in this specification, "A to B" representing a numerical range means "A or more and B or less."
[0007] 1. Method for forming graft layer A method for forming a graft layer according to an embodiment of the present disclosure includes a contacting step of contacting a substrate containing a polymer A with a treatment liquid containing a compound B and a polymer C in a solvent D. The contacting step includes a polymerization step of graft polymerizing the compound B onto the polymer A constituting at least a part of the surface of the substrate.
[0008] In this specification, a polymer formed by polymerization of compound B is referred to as "polymer B". In addition, in this specification, "graft layer" means a layer formed by graft polymerization of polymer B to a substrate. In other words, the graft layer is a layer formed on the surface of a substrate and containing polymer B. The graft-polymerized polymer B is also referred to as a "graft chain".
[0009] With the above-mentioned configuration, a graft layer containing polymer B can be efficiently formed on at least a part of the surface of the substrate. Specifically, the efficiency of graft polymerization of compound B is improved by the excluded volume effect and gel effect of polymer C contained in solvent D. The excluded volume effect and gel effect will be described below.
[0010] FIG. 1 is a schematic diagram illustrating the excluded volume effect. Polymer C has a volume in the treatment liquid. Generally, repulsive force acts between polymers C, so that the proximity between polymers C is limited. Therefore, as shown in FIG. 1, the area in which compound B can exist is narrower in treatment liquid 1001 to which polymer C has been added than in treatment liquid 1000 to which polymer C has not been added. This is called the excluded volume effect. As a result, the apparent concentration of compound B in the treatment liquid and / or the consumption rate of compound B increases, and the graft polymerization efficiency of compound B is improved.
[0011] FIG. 2 is a schematic diagram illustrating the gel effect. As described above, since the treatment liquid contains polymer C, the entire treatment liquid becomes highly viscous. Then, the movement of polymer B having a growing radical is restricted, and as shown in FIG. 2, the termination reaction, which is a bimolecular reaction between polymers B, is reduced. That is, when polymers B having a growing radical react with each other, further polymerization at the end of polymer B may be terminated, but if the treatment liquid has a high viscosity, the termination of this polymerization is reduced. This is called the gel effect. As a result, the apparent consumption rate of compound B increases.
[0012] The above two factors make it possible to efficiently form graft chains having a length equal to or greater than that of conventional methods and / or graft layers having a thickness equal to or greater than that of conventional methods on the surface of a substrate containing polymer A, using a lower concentration of compound B than that of conventional methods.
[0013] <1-1. Processing solution> A treatment liquid according to an embodiment of the present disclosure contains a compound B, a polymer C, and a solvent D, and is a treatment liquid for forming a graft layer by graft polymerization of the compound B on at least a part of the surface of a substrate containing a polymer A. The treatment liquid may contain the polymer C in addition to the compound B at a stage before the start of graft polymerization.
[0014] By forming a graft layer using the treatment liquid of the present disclosure, the amount of compound B used and the amount of waste can be reduced compared to the conventional technology. That is, the production efficiency can be improved and the burden on the environment can be reduced. In addition, it is possible to reduce the amount of polymerization initiator used, reduce the intensity of the light irradiated in photoinitiated graft polymerization, reduce the polymerization temperature in thermally initiated graft polymerization, etc. Therefore, it is expected that the deterioration of the substrate due to light irradiation will be reduced and the applicable compounds will be expanded.
[0015] Polymer B is formed by polymerization of compound B. Compound B forms a graft layer by graft polymerization. Compound B may be of one type or of multiple types.
[0016] The compound B may be electrically neutral. This can reduce interactions within the compound B and / or between the compounds B. In this specification, "electrically neutral" means that the compound does not have a group that ionizes to become an ion in an aqueous solution with a pH near neutral (pH 6 to 8), or, even if it does have a group that becomes a cation and a group that becomes an anion, the sum of the charges is substantially zero. Here, "substantially" means that the sum of the charges is zero, or, even if it is not zero, it is small enough not to adversely affect the effects of the present disclosure.
[0017] Compound B may have a phosphorylcholine group, which allows the graft layer to maintain high biocompatibility and / or good lubrication for a long period of time.
[0018] Compound B may further have a polymerization initiating group. For example, compound B may be a polymerizable monomer having a phosphorylcholine group at one end and a polymerization initiating group capable of graft polymerizing with the substrate at the other end.
[0019] The compound B may have a polymerizable methacrylic acid unit as the polymerization initiation group, which makes it possible to easily form a graft layer.
[0020] Examples of compound B having a phosphorylcholine group include 2-methacryloyloxyethyl phosphorylcholine, 2-acryloyloxyethyl phosphorylcholine, 4-methacryloyloxybutyl phosphorylcholine, 6-methacryloyloxyhexyl phosphorylcholine, and ω-methacryloyloxyethylene phosphorylcholine. Hereinafter, 2-methacryloyloxyethyl phosphorylcholine is also referred to as "MPC". In addition, a polymer obtained by polymerizing MPC is also referred to as poly(MPC) or PMPC.
[0021] MPC has the chemical structure shown in the structural formula below, and is a polymerizable monomer having a phosphorylcholine group and a polymerizable methacrylic acid unit.
[0022] [ka] MPC is easily polymerized by radical polymerization, and can form a homopolymer with a high molecular weight (Ishihara et al., Polymer Journal 22, p355 (1990)). Therefore, when a graft layer is formed as an assembly of polymer chains polymerized from MPC, the graft bond between the MPC polymer chains and the substrate surface can be achieved under relatively mild conditions. Furthermore, by forming high-density graft chains and / or graft layers, a large amount of phosphorylcholine groups can be formed on the substrate surface.
[0023] The graft layer can be formed not only as a homopolymer composed of a single polymerizable monomer having a phosphorylcholine group, but also as a copolymer composed of a polymerizable monomer having a phosphorylcholine group and, for example, another vinyl compound monomer, which can impart a function such as improved mechanical strength to the graft layer depending on the type of the other vinyl compound monomer used.
[0024] Other examples of compound B include polyethylene glycol dimethacrylate and monomers having a betaine structure (methacryloyloxyethyl carboxybetaine, methacryloyloxyethyl sulfobetaine, methacryloyloxyethyl amidobetaine).
[0025] The concentration of compound B in the treatment liquid may be appropriately changed depending on the type of compound B, and may be, for example, 0.05 to 0.25 mol / L, 0.10 to 0.25 mol / L, or 0.10 to 0.20 mol / L. When the concentration of compound B is within the above range, production costs and environmental impacts can be reduced, a graft layer having sufficient density and thickness can be formed, and the wettability and abrasion resistance of the graft layer surface can be improved.
[0026] The polymer C brings about the excluded volume effect and the gel effect as described above. The polymer C is not particularly limited as long as it is a polymer that does not interfere with the graft polymerization of the compound B. The polymer C may be an organic polymer or an inorganic polymer. From the viewpoint of solubility in the solvent D, the polymer C may be an organic polymer. The polymer C may be one type or multiple types.
[0027] The polymer C may be electrically neutral. "Electrically neutral" is as described above. If the polymer C is electrically neutral, the interaction within the polymer C and / or between the polymers C can be reduced, and further, the interaction between the polymer C and the compound B and / or the polymer B can also be reduced.
[0028] The weight average molecular weight of the polymer C may be 10,000 or more, may be 10,000 to 1,000,000, or may be 100,000 to 1,000,000. With the above-mentioned configuration, the excluded volume effect of the polymer C in the treatment liquid is improved, and the efficiency of the graft polymerization of the compound B is improved. The weight average molecular weight can be measured, for example, by gel permeation chromatography.
[0029] The polymer C may have a phosphorylcholine group. The monomer constituting the polymer C may be the same compound as the compound B. The polymer C may be, for example, poly(2-methacryloyloxyethyl phosphorylcholine).
[0030] On the other hand, polymer B and polymer C may be different compounds that do not react with each other. This allows compound B to be used only for graft polymerization onto the substrate, thereby improving the efficiency of graft polymerization of compound B.
[0031] Examples of polymer C include polymers having phosphorylcholine groups, as well as polyethylene glycol polymethacrylate, various polymers having betaine groups, starch, sucrose, hyaluronic acid, and the like.
[0032] The concentration of polymer C in the treatment liquid can be appropriately changed depending on the type of polymer C, and may be, for example, 1 μmol / L or more, or 1 to 1000 μmol / L. When the concentration of polymer C is within the above range, the excluded volume effect of polymer C in the treatment liquid can be improved, and the efficiency of graft polymerization of compound B can be improved. Even when polymer B is used as polymer C, the amount of compound B to be discarded can be reduced compared to when polymer B is not used.
[0033] Furthermore, the dissolved oxygen concentration in the treatment solution before the start of graft polymerization may be 6.0 mg / L or less, or may be 0.2 mg / L or less. When the dissolved oxygen concentration is within the above range, the inhibition of polymerization of compound B caused by dissolved oxygen can be reduced.
[0034] Solvent D is not particularly limited, and may be a hydrophilic solvent or a hydrophobic solvent. From the viewpoint of environmental burden, a hydrophilic solvent may be used. Examples of hydrophilic solvents include water, saline, sugar water, and a water / ethanol mixed solution. Examples of hydrophobic solvents include alcohol, acetone, and hexane. Solvent D may contain at least water.
[0035] The solvent D may be a good solvent for at least one of the polymer B obtained by polymerization of the compound B and the polymer C. The solvent D may be a good solvent for both the polymer B and the polymer C.
[0036] In this specification, the term "good solvent" refers to a solvent in which the solubility of the target compound is relatively high compared to a poor solvent described later. With the above-mentioned configuration, a large amount of polymer B and / or polymer C can be dissolved in the solvent, thereby improving the efficiency of graft polymerization.
[0037] In addition, the solvent D may be a good solvent for the compound B. If the solvent D is a good solvent for the compound B, the mobility of the compound B in the solvent D can be improved, and therefore the efficiency of the graft polymerization of the compound B can be improved.
[0038] When the polymer generated by polymerization is to be recovered from the solvent, a poor solvent may be used as the solvent. However, in the method for forming a graft layer of the present disclosure, a good solvent for polymer B can be used as described above.
[0039] The treatment liquid may further contain an inorganic salt soluble in the solvent D. This can improve the efficiency of the graft polymerization of the compound B.
[0040] When the solvent D is a hydrophilic solvent, a water-soluble inorganic salt may be used as the inorganic salt. Examples of the water-soluble inorganic salt include alkali metal salts and alkaline earth metal salts. Examples of the alkali metal salts include sodium salts, potassium salts, lithium salts, and cesium salts. Examples of the alkaline earth metal salts include magnesium salts, calcium salts, strontium salts, barium salts, and radium salts. Inorganic salts can be classified according to the type of counter anion, and include halides (e.g., chlorides, fluorides, bromides, iodides, etc.), phosphates, carbonates, nitrates, and hydroxides. The water-soluble inorganic salt is, for example, one or more selected from the group consisting of sodium chloride, potassium chloride, calcium chloride, and magnesium chloride.
[0041] The concentration of the inorganic salt in the treatment liquid may be, for example, 0.01 to 5.0 mol / L, 1.0 to 5.0 mol / L, or 1.0 to 3.0 mol / L. This concentration allows efficient formation of a graft layer having a sufficient graft density.
[0042] <1-2. Base material> The substrate is a target for forming a graft layer. The substrate may contain polymer A on at least a portion of its surface. The substrate may contain functional compounds such as antioxidants, crosslinking agents, and / or reinforcing materials such as carbon fibers.
[0043] Examples of the polymer A include polyolefins and aromatic polyether ketones. The polymer A may be one type or multiple types. Examples of the polyolefin include polyethylene. Examples of the polyethylene include ultra-high molecular weight polyethylene (UHMWPE) from the viewpoint of excellent mechanical properties such as abrasion resistance, impact resistance, and deformation resistance. Examples of the aromatic polyether ketone include polyether ether ketone (PEEK) from the viewpoint of excellent mechanical properties such as impact resistance and deformation resistance.
[0044] The polymer A may contain free radicals. In this specification, the term "free radical" refers to a molecule having an unpaired electron and paramagnetic properties. The content of free radicals can be measured by electron spin resonance. The amount of free radicals is 1.0×10 14 spins / g or more, and may be 1.0×10 14 ~1.0×10 20 spins / g, 1.0×10 15 ~1.0×10 20 It may be spins / g.
[0045] The higher the molecular weight of the polymer constituting the substrate, the higher the wear resistance tends to be. In the case of a substrate containing polyolefin, the molecular weight of the polymer constituting the substrate may be 1 million or more, 1 million to 7 million, 3 million to 7 million, and particularly 3 million to 4 million. In the case of a substrate containing aromatic polyether ketone, the molecular weight of the polymer constituting the substrate may be 50,000 or more, 80,000 to 500,000, or 80,000 to 200,000. In this specification, the molecular weight of the polymer constituting the substrate means the molecular weight determined by the following formula (1) by viscosity measurement at 135 ° C. of a decahydronaphthalene (decalin) solution containing the polymer. Molecular weight=5.37×10 4 ×(intrinsic viscosity) 1.49 (1) From the viewpoint of mechanical properties such as impact resistance and deformation resistance, the density of the polymer constituting the substrate is 0.927 to 0.944 g / cm for a substrate containing polyolefin. 3 In the case of a substrate containing an aromatic polyether ketone, the density is 1.20 to 1.55 g / cm. 3 may be also possible.
[0046] <1-3. Contact process> The contacting step is a step of contacting a substrate containing a polymer A with a treatment liquid containing a compound B and a polymer C in a solvent D. In the contacting step, at least a part of the substrate may be contacted with the treatment liquid. For example, a part of the surface of the substrate on which the polymer A is present may be contacted with the treatment liquid, or the entire substrate may be contacted with the treatment liquid.
[0047] The method of contacting the substrate with the treatment liquid is not particularly limited, and can be any method. From the viewpoint of efficiently forming a graft layer, the substrate may be immersed in the treatment liquid. The time for contacting the substrate with the treatment liquid is also not particularly limited, but from the viewpoint of carrying out the polymerization step described later, the substrate may be contacted for 5 minutes or more.
[0048] <1-4. Polymerization process> The polymerization step is a step of graft-polymerizing the compound B to the polymer A constituting at least a part of the surface of the base material during the contact step. The polymerization step can be carried out simultaneously with the contact step. The method of graft polymerization is not particularly limited, and may be, for example, photoinitiated graft polymerization or thermally initiated graft polymerization.
[0049] In the case of photoinitiated graft polymerization, polymer B formed by polymerizing compound B can be stably fixed on the surface of the substrate. Furthermore, photoinitiated graft polymerization can increase the density of the graft layer by forming polymer B at a high density on the surface of the substrate.
[0050] Photoinitiated graft polymerization may be initiated by visible light or ultraviolet light. When the surface of the substrate is irradiated with ultraviolet light, compound B near the surface is polymerized to generate polymer B. The generated polymer B is covalently bonded to the surface of the substrate. Polymer B is densely grafted to the surface to form a graft layer that covers the substrate surface as a whole. At this time, the substrate may be heated. Photoinitiated graft polymerization can be controlled by heating the substrate and the treatment liquid in contact with the substrate.
[0051] The surface of the substrate may contain a photopolymerization initiator. For example, the surface of the substrate may be coated with a photopolymerization initiator before the substrate is brought into contact with the treatment liquid. In this case, the photopolymerization initiator radicals generated by ultraviolet irradiation form polymerization initiation points on the substrate surface. Compound B reacts with the polymerization initiation points to initiate graft polymerization, resulting in polymer B.
[0052] The wavelength of the ultraviolet light to be irradiated is, for example, 300 to 400 nm. As a light source for irradiating ultraviolet light, for example, a high pressure mercury lamp (UVL-400HA manufactured by Riko Kagaku Sangyo Co., Ltd.) or an LED (MeV365-P601JMM manufactured by YEV Corporation) can be used. The irradiation time of ultraviolet light may be 11 to 90 minutes, or may be 23 to 90 minutes.
[0053] The heating temperature and heating time of the thermally initiated graft polymerization are not particularly limited, but the heating temperature may be equal to or lower than the melting point of polymer A and / or polymer B and / or polymer C, and may be equal to or lower than the boiling point of solvent D. The heating temperature may be, for example, 25 to 150° C., and the heating time may be, for example, 10 to 180 minutes.
[0054] The graft polymerization may be initiated by irradiating with gamma rays. The irradiation time of gamma rays is not particularly limited, but may be, for example, 5 to 120 minutes.
[0055] After the graft polymerization is completed, the treatment solution may be removed by washing, and a sterilization treatment using gamma ray irradiation, ethylene oxide gas, or the like may be further carried out.
[0056] 2. Method for Producing the Composite A method for producing a composite according to an embodiment of the present disclosure is a method for producing a composite including a substrate and a graft layer covering at least a part of the surface of the substrate. The method for producing the composite includes a step of forming a graft layer by graft polymerization of a compound B on at least a part of the surface of a substrate including a polymer A by the above-mentioned method for forming a graft layer. Explanation of the matters already explained in [1. Method for forming a graft layer] will be omitted below.
[0057] <2-1. Base material formation process> The manufacturing method may use a commercially available product as the substrate, or may include a substrate forming step before the step of forming the graft layer. The substrate is obtained, for example, by putting a powdered, granular or pellet-like polymer A into a mold, followed by compression molding, extrusion molding or injection molding. Examples of polymer A include the above-mentioned UHMWPE and PEEK. Although UHMWPE and PEEK are thermoplastic resins, they have low fluidity even at or above their melting temperature. Therefore, solid UHMWPE or PEEK may be put into a mold and molded under high heat and pressure conditions. Reinforcing materials such as antioxidants, crosslinking agents and carbon fibers may be put into the mold together with polymer A.
[0058] <2-2. Crosslinking process> The method for producing a composite according to an embodiment of the present disclosure may include a crosslinking step for generating a crosslinked structure within the molecule of polymer A, prior to the step of forming a graft layer, for example, between the step of forming a substrate and the step of forming a graft layer. This makes it possible to obtain a substrate having further improved mechanical properties, such as abrasion resistance.
[0059] The crosslinking step may include a step of irradiating the substrate with high energy rays. This step is also called a high energy ray irradiation step. By irradiating the substrate with high energy rays, free radicals are generated. This allows the molecular chains of polymer A to be bonded together, resulting in polymer A having a crosslinked structure. By generating a crosslinked structure between the molecular chains, mechanical properties such as abrasion resistance and impact resistance are improved.
[0060] Although the crosslinking reaction can be carried out by adding a crosslinking agent, it tends to be difficult to completely remove the unreacted crosslinking agent. Therefore, in consideration of the effect of the unreacted crosslinking agent on the living body, the crosslinking reaction may be carried out by irradiation with high energy rays.
[0061] Examples of high energy radiation include X-rays, gamma rays, and electron beams. The exposure dose of high energy radiation may be, for example, 25 to 200 kGy, or 50 to 150 kGy. Examples of high energy radiation sources that can be used include a radiation device using Co (cobalt) 60 as a radiation source as a gamma ray source, an accelerator that emits electron beams, and a device that irradiates X-rays.
[0062] The crosslinking step may further include a heat treatment step after the high energy ray irradiation step. In the heat treatment step, the free radicals generated by the high energy ray irradiation step are more efficiently consumed in the crosslinking reaction to promote intramolecular crosslinking. The temperature range of the heat treatment may be 110 to 130°C. The treatment time of the heat treatment may be 2 to 12 hours.
[0063] [3. Uses of the composite] The composite produced by the above-mentioned production method can be used, for example, as a medical device member, an industrial device member, etc. Examples of the medical device member include an artificial joint member, an artificial blood vessel, an artificial heart, various stents, etc.
[0064] The artificial joint to which the artificial joint member is applied is not particularly limited, and examples thereof include an artificial hip joint, an artificial knee joint, an artificial ankle joint, an artificial shoulder joint, an artificial elbow joint, an artificial finger joint, an artificial intervertebral disc, and the like. For example, an artificial hip joint may include a femoral head and an acetabulum. The artificial joint member according to one embodiment of the present disclosure can be applied to the femoral head or the acetabulum, or both. For example, when the artificial joint member is used for either one of the femoral head and the acetabulum, the other may be a member containing a metal such as stainless steel or a cobalt chromium alloy; a ceramic such as alumina or zirconia; or a polymer such as UHMWPE or PEEK. In addition, for example, the femoral head and the acetabulum may be formed of different materials. For example, the femoral head may be formed of a polymer, ceramic, or metal material, and the base material of the acetabulum may be formed of, for example, a polymer material.
[0065] An example of using the composite according to an embodiment of the present disclosure as an acetabular cup of an artificial hip joint as an artificial joint member will be described below. FIG. 3 is a schematic diagram of an artificial hip joint 1 according to an embodiment of the present disclosure. FIG. 4 is a schematic diagram of an acetabular cup 10 according to an embodiment of the present disclosure. The artificial hip joint 1 is composed of an acetabular cup 10 fixed to an acetabulum 94 of a hip bone 93, and a femoral stem 20 fixed to a proximal end of a femur 91. The acetabular cup 10 has a cup base material 12 having a substantially hemispherical acetabular fixing surface 14 and a substantially hemispherically recessed sliding surface 16, and a graft layer 30 covering the sliding surface 16. The acetabular cup 10 functions as a hip joint by fitting and sliding the head 22 of the femoral stem 20 into the recess 161 in which the graft layer 30 is formed. The acetabular cup 10 functions as a hip joint. The acetabular fixing surface 14 is an outer surface arranged on the side close to the acetabulum 94. The bearing surface 16 is also the inner surface or contact surface that contacts the head 22 .
[0066] 3 and 4, in the acetabular cup 10, the bearing surface 16 of the cup substrate 12 is covered with a graft layer 30. The graft layer 30 is obtained by graft polymerization of a polymer B in which a compound B is polymerized, onto the bearing surface 16. The graft layer 30 may be disposed only on the acetabular cup 10, or may be disposed on both the acetabular cup 10 and the femoral head 22.
[0067] The graft layer 30 has a structure similar to that of a biological membrane, has a high affinity with the lubricating fluid in the joint, and can retain the lubricating fluid inside the membrane. The graft layer 30 also has a high density of phosphate groups. Therefore, the acetabular cup 10 exhibits excellent wear resistance. EXAMPLES
[0068] Hereinafter, one embodiment of the present disclosure will be described in more detail based on examples and comparative examples, but the embodiment of the present disclosure is not limited to these.
[0069] Example 1 2-methacryloyloxyethyl phosphorylcholine (MPC) monomer was used as compound B, polyMPC (PMPC) was used as polymer C, and pure water was used as solvent D. The weight average molecular weight of polymer C was 200,000 to 1,000,000. PMPC, NaCl, and MPC were dissolved in pure water to prepare a treatment liquid. The PMPC concentration in the treatment liquid was 10 μmol / L, the NaCl concentration was 2.5 mol / L, and the MPC concentration was 0.05 mol / L. Polymer A had a molecular weight of 3,000,000 to 4,000,000, and a density of 0.93 g / cm. 3 A square piece of ultra-high molecular weight polyethylene (cross section: 10 mm x 3 mm, length: 50 mm) was used as the substrate. The square piece was immersed in the prepared treatment solution and then irradiated with ultraviolet light for 90 minutes. After the ultraviolet light irradiation was completed, the square piece was pulled out and thoroughly washed with pure water and ethanol to obtain a test piece with a PMPC graft layer formed on the surface of the substrate.
[0070] Test pieces were also prepared in the same manner as above using treatment solutions in which the MPC concentrations were changed to 0.08 mol / L, 0.1 mol / L, 0.15 mol / L, 0.2 mol / L, 0.25 mol / L, and 0.5 mol / L.
[0071] Comparative Example 1 A test piece was prepared in the same manner as in Example 1, except that the treatment liquid did not contain polymer C. In addition, in Comparative Example 1, a test piece was also prepared using a treatment liquid to which neither compound B nor polymer C was added.
[0072] [Measurement of static contact angle of water] The hydrophilicity of each test piece was evaluated by measuring the contact angle (static contact angle of water) when pure water was dropped on the surface of each test piece on which the graft layer was formed. The static contact angle of water was evaluated by the sessile drop method using a surface contact angle measuring device (DM300 manufactured by Kyowa Interface Science Co., Ltd.). Specifically, in accordance with the ISO15989 standard, a 1 μL drop of pure water was dropped on the surface of the test piece, and the contact angle was measured 60 seconds later.
[0073] [Measurement of the thickness of the graft layer] For each test piece, the test piece was embedded in epoxy resin and then stained with ruthenium tetrachloride. Ultrathin sections were then cut from the test piece using an ultramicrotome. Electron microscope images of the cut surfaces of the ultrathin sections were obtained using a transmission electron microscope (TEM) with an acceleration voltage of 100 kV. For each electron microscope image obtained, the film thickness on the cut surface was measured at 10 points, and the average value was calculated to determine the thickness of the graft layer.
[0074] [Evaluation results] FIG. 5 is a graph showing the relationship between the MPC concentration in the treatment liquid and the static contact angle of water in Example 1 and Comparative Example 1. In FIG. 5, black circles (polymer C(+)) indicate the results of the test piece of Example 1 prepared by adding polymer C, and white circles (polymer C(-)) indicate the results of the test piece of Comparative Example 1 prepared without adding polymer C. From FIG. 5, it was found that in Example 1, even if the concentration of compound B in the treatment liquid was low, a graft layer with high hydrophilicity could be formed. In particular, the contact angle of the test piece in the treatment liquid having an MPC concentration of 0.08 to 0.25 mol / L was low, being 45° or less. Moreover, the contact angle of the test piece in the example in which the MPC concentration in the treatment liquid was 0.1 to 0.2 mol / L was particularly low.
[0075] Fig. 6 is a graph showing the relationship between the MPC concentration in the treatment solution and the thickness of the graft layer in Example 1 and Comparative Example 1. The meanings of the black and white circles in Fig. 6 are the same as those in Fig. 5. Fig. 6 shows that in Example 1, even if the treatment solution had a low concentration of MPC, it was possible to form a graft layer having a thickness equal to or greater than that of the conventional technology. In particular, when the MPC concentration in the treatment solution was 0.08 to 0.25 mol / L, the thickness of the graft layer was 50 to 250 nm, which was greater than that of the test piece in Comparative Example 1 in which polymer C was not added.
[0076] The invention according to the present disclosure has been described above based on the drawings and examples. However, the invention according to the present disclosure is not limited to the above-mentioned embodiments. In other words, the invention according to the present disclosure can be modified in various ways within the scope of the present disclosure, and the embodiments obtained by appropriately combining the technical means disclosed in the different embodiments are also included in the technical scope of the invention according to the present disclosure. In other words, it should be noted that a person skilled in the art can easily make various modifications or corrections based on the present disclosure. It should also be noted that these modifications or corrections are included in the scope of the present disclosure. [Industrial Applicability]
[0077] The invention according to the present disclosure can be used as a method for forming a graft layer. [Explanation of symbols]
[0078] 1. Artificial hip joint 10 Acetabular cup (artificial joint component) 12 Cup base material (base material) 30 Graft layer
Claims
1. a contacting step of contacting a substrate containing a polymer A with a treatment liquid containing a compound B and a polymer C in a solvent D; a polymerization step of graft-polymerizing the compound B onto the polymer A constituting at least a part of the surface of the base material during the contact step, The weight average molecular weight of the polymer C is 10,000 or more, The compound B has a phosphorylcholine group. Method for forming a graft layer.
2. The method for forming a graft layer according to claim 1 , wherein the solvent D is a good solvent for at least one of the polymer B obtained by polymerization of the compound B and the polymer C.
3. The method for forming a graft layer according to claim 1 or 2, wherein the treatment liquid further contains an inorganic salt soluble in the solvent D.
4. The method for forming a graft layer according to any one of claims 1 to 3, wherein the compound B has a polymerizable methacrylic acid unit.
5. The method for forming a graft layer according to any one of claims 1 to 4, wherein the polymer A is a polyolefin or an aromatic polyether ketone.
6. A method for producing a composite comprising a substrate and a graft layer covering at least a portion of a surface of the substrate, the method comprising: forming a graft layer by graft polymerization of a compound B on at least a portion of a surface of the substrate comprising a polymer A by the method for forming a graft layer according to any one of claims 1 to 5.
7. The method for producing a composite according to claim 6 , wherein the composite is a medical device component.
8. The method for producing a composite according to claim 7 , wherein the medical device component is an artificial joint component.
9. A compound B and a polymer C are contained in a solvent D, The weight average molecular weight of the polymer C is 10,000 or more, The compound B has a phosphorylcholine group. A treatment liquid for forming a graft layer by graft polymerization of the compound B on at least a part of the surface of a substrate containing a polymer A.
10. The treatment liquid according to claim 9 , wherein the solvent D is a good solvent for at least one of a polymer B formed by polymerization of the compound B and the polymer C.
11. The treatment liquid according to claim 9 or 10, further comprising an inorganic salt soluble in the solvent D.
Citation Information
Patent Citations
Method for grafting previously formed hydrophilic polymer onto base hydrophobic polymer, and coating composition therefor
JP1994087968A
Coating of polymeric substrate, use of coated polymeric substrate and product composed thereof
JP1999080394A
Method for producing cell culture support
JP2013162796A
Manufacturing method of medical equipment
JP2017213218A
Medical component and production method thereof
JP2020043891A
